All In Biotech

Drug Trial Radar · NCT05977140

CDI-988 Safety Study in Healthy Participants

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of Oral CDI-988 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

94

Actual

Start

Sep 27, 2023

Primary completion

May 23, 2025

Study completion Jul 23, 2025

Sponsor

Lead sponsor
Cocrystal Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Cocrystal Pharma Australia Pty Ltd.; Beyond Drug Development Pty Ltd.; Resolutum Global Pty Ltd.; Scientia Clinical Research Pty Ltd
First posted
Aug 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety and pharmacokinetics (PK, the amount of drug in the blood) of a new drug called CDI-988 in healthy volunteers. The main questions it aims to answer are: * Are there any side effects of the drug? * What is the amount of drug that reaches the bloodstream? Participants will be assigned by chance to take either CDI-988 or placebo by mouth and have physical exams, electrocardiograms (ECGs), vital signs, and blood tests to look for any side effects.

Conditions

  • Healthy Volunteers

Interventions

  • CDI-988Drug

    SARS-CoV-2 3CL protease inhibitor

  • PlaceboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Up to 17 days
  2. Laboratory AbnormalitiesTime frame: Up to 17 days
  3. Vital SignsTime frame: Day 1 to 7 days after last dose
  4. ECGsTime frame: Day 1 to 7 days after last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research Pty Ltd

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.